TG Therapeutics: Phase 1 Results Of Subcutaneous Briumvi Are A De-Risking Event
Source: SeekingAlpha
2026-06-04 09:00:00 ET
Shares of TG Therapeutics, Inc. ( TGTX ) ("TG") rallied yesterday after the company presented phase 1 results of subcutaneous ("SC") Briumvi. The results look as good as one would have expected, from bioavailability to safety and tolerability, and TG now looks well-positioned to have a new product offering that nearly doubles the addressable market....
Read the full article on Seeking Alpha
For further details see:
TG Therapeutics: Phase 1 Results Of Subcutaneous Briumvi Are A De-Risking Event
Novartis AG
NASDAQ: NVS
NVS Trading
2.28% G/L:
$146.94 Last:
1,581,529 Volume:
$146.46 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
